<DOC>
	<DOC>NCT01490567</DOC>
	<brief_summary>The objective of the study was to study the effects of donepezil on cognition in patients with schizophrenia. The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.</brief_summary>
	<brief_title>A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia</brief_title>
	<detailed_description>The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.The trial will be complete in 2012.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>DSMIV diagnosis of schizophrenia as determined by the Structured Clinical Interview for DSMIV Axis I DisordersClinician Version; Between 18 and 40 years of age; Duration of the illness must be longer than 2 year; Patient's current antipsychotic medication regimen must be stable; Must be in a stable living arrangement; Patient has mental retardation or severe organic brain syndromes; Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening; Has suicidal attempts or ideation or violent behavior within the last 12 months; Patient has a history of alcohol/drug dependence;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Impaired Cognition Schizophrenia</keyword>
</DOC>